Drugmaker partners Organon and Samsung Bioepis said on Saturday that they had launched a far cheaper copycat version of AbbVie’s blockbuster arthritis drug Humira, while two other drugmakers entered the market with much more modest discounts to the branded medicine's list price.
July 1 - Drugmaker partners Organon and Samsung Bioepis said on Saturday that they had launched a far cheaper copycat version of AbbVie’s
The copycat drug called Hadlima will be listed at $1,038 per month, representing an 85% discount of Humira’s current $6,922 monthly price, the companies said. Germany-based Boehringer Ingelheim later said it released its rival version of Humira, Cyltezo, at a 5% to 7% price cut from the list price of the branded medicine.
Organon and Samsung Bioepis did not say if they had struck deals with pharmacy benefit managers , which negotiate insurance coverage on behalf of large employers and health insurance plans, to secure reimbursement of Hadlima for patients.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Organon, Samsung Bioepis launch copycat for arthritis drug Humira at 85% discountDrugmaker partners Organon and Samsung Bioepis said on Saturday that they had launched a far cheaper copycat version of AbbVie’s blockbuster arthritis drug Humira, while another drugmaker entered the market with a much more modest discount to the branded medicine's list price.
Weiterlesen »
Cheaper competition for Humira is hitting the market, but savings will depend on your insurancePatients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July.
Weiterlesen »
Cheaper competition for Humira is hitting the market, but savings will depend on your insurancePatients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July.
Weiterlesen »
For AbbVie’s blockbuster Humira, cheaper competitors pose surprisingly little threat, analysts sayLower-price biosimilar competition for top-selling drug launching this weekend.
Weiterlesen »
Humira, the world’s top-selling drug, faces an upcoming test from low cost alternativesNew Humira alternatives will be available in July. This could make the drug that now costs nearly $80,000 per year more affordable.
Weiterlesen »
Will lower-cost Humira pharmaceutical options soon be available to patients?Seven new alternatives to the high-cost Humira drug will be available in July. Some will be offered at significantly lower prices, but will patients see big...
Weiterlesen »